Overview
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.
Description
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.
Eligibility
Inclusion Criteria:
- ≥18,Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- RET Fusion Positive
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion Criteria:
- - Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women